Clinical Evaluation of the Effect of Metformin in Sepsis

NCT ID: NCT05979038

Last Updated: 2023-09-13

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 110 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-09-10
• Study Completion Date: 2024-07-10

Brief Summary

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. It is considered a condition that arises when the body's response to an infection injures its own tissues and organs. The pathogenesis of sepsis is very complicated as it involves imbalance in inflammatory response, immune dysfunction, mitochondrial damage, coagulopathy, neuroendocrine immune network abnormalities, endoplasmic reticulum stress, autophagy, and other pathophysiological processes, and leads to organ dysfunction. Inflammatory Imbalance represents the most critical basis of sepsis pathogenesis. Sepsis is associated with many biochemical abnormalities that is correlated with patients' prognosis and risk of mortality including increased levels of lactate, procalcitonin and inflammatory cytokines as TNF alpha.

Metformin is an oral anti-diabetic drug from the class of biguanides. It is the first line treatment of diabetes type 2. It is widely used as it has good safety profile, low side effect and cheap cost. Metformin has been reported to have an anti-inflammatory and anti-microbial effect.

Some studies have shown that metformin has a beneficial effect in sepsis patients. Our study will be the first prospective controlled randomized trial to assess the clinical outcome of metformin in patients with sepsis.

Detailed Description

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. It is considered a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs (Singer et al., 2016a). Organ dysfunction can be defined as an increase in the Sequential (sepsis related) Organ Failure Assessment (SOFA) score more than two points consequent to the infection. A SOFA score more than two points indicates that an overall mortality risk of approximately 10% in hospital population with suspected infection.(Singer et al., 2016b). Septic shock is defined as subset of sepsis in which circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than sepsis alone. Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP (mean arterial pressure) more than or equal 65mmHg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate volume resuscitation (Seymour et al., 2016).

Sepsis and septic shock are major healthcare problems, affecting millions of people around the world each year with a mortality rate between one in three and one in six of those it affects (Evans et al., 2021). According to a meta-analysis conducted in 2020, it was found that the incidence of sepsis was 189 hospital-treated sepsis cases per 100,000 person-years with a 26.7% mortality rate. In ICU patients, the incidence was 58 per 100,000 person-years with a mortality rate of 41.9% prior to hospital discharge (Fleischmann-Struzek et al., 2020).

The pathogenesis of sepsis is very complicated as it involves imbalance in inflammatory response, immune dysfunction, mitochondrial damage, coagulopathy, neuroendocrine immune network abnormalities, endoplasmic reticulum stress, autophagy, and other pathophysiological processes, and leads to organ dysfunction. Inflammatory Imbalance represents the most critical basis of sepsis pathogenesis. The host's initial acute response to invasive pathogens causes macrophages to engulf the pathogens and produce a range of pro-inflammatory cytokines, and this can trigger cytokine storms and activate the innate immune system. The activation of the innate immune system is mediated by pattern-recognition receptors (PRRs), which initiate a series of activation in immune cells by detecting damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs), and thus upregulate the expression of inflammation related genes. In the immune response to sepsis, both exogenous factors derived from the pathogen (e.g., lipopolysaccharide (LPS)) and endogenous factors released by injured cells (e.g., high-mobility group box-1 (HMGB-1) protein) can interact with various PRRs, such as Toll-like receptors (TLRs), which leads to the activation of several pathways including p38 mitogen-activated protein kinase (MAPK), and nuclear factor-κB (NF-κB) signaling pathways. These events are followed by the production of inflammatory cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor-α (TNF-α), interferon (IFN) regulatory factor 7 (IRF7), and adaptor protein 1 (AP-1) (Huang, Cai and Su, 2019).

Moreover, studies have also shown that in early stages of sepsis, exaggerated endothelial activation, vascular leakage, disturbance of blood flow, as well as other derangements cause the loss of vascular integrity, which contributes significantly to sepsis-associated organ failure. Therapies interfering endothelial activation are potential to attenuate sepsis-induced organ dysfunction (Tian et al., 2019) Sepsis is associated with many biochemical abnormalities that is correlated with patients' prognosis and risk of mortality including increased levels of lactate, procalcitonin and inflammatory cytokines as TNF alpha.(Cho and Choi, 2014) Despite great efforts was done to understand the pathogenesis of sepsis and investigate therapeutic strategies, the management of sepsis remains a clinical challenge (Tian et al., 2019). Till current date the pathogenesis of sepsis is not completely clear but most of the studies suggested that the release of inflammatory factors by patient's innate immune cell plays an important role in the disease progression (Liang et al., 2019). Recently several studies revealed the anti-inflammatory effect of some drugs in sepsis. One of the drugs that showed anti-inflammatory effect in these studies is metformin (Han et al., 2018).

Metformin is an oral anti-diabetic drug from the class of biguanides. It is the first line treatment of diabetes type 2. It is widely used as it has good safety profile, low side effect and cheap cost (Malik et al., 2018). Studies have shown that metformin modulates cellular metabolism by two inter-related mechanisms. It transiently inhibits mitochondrial complex I of the electron transport chain, decreasing the production of mitochondrial reactive oxygen species and complex I inhibition also leads to an increase of the adenosine monophosphate/adenosine triphosphate (ATP) ratio (a critical signal of energy imbalance), which activates the AMPK. AMPK is a ubiquitous, critical cellular energy sensor with pleiotropic effects on cell metabolism, which can protect the cell by shutting down ATP consuming processes, promoting fatty acid oxidation and controlling the turn-over cycle of injured mitochondria. Metformin and AMPK activation improve endothelial function, reducing capillary leak and inducible nitric oxide synthase and increasing endothelial nitric oxide synthase activity potentially improving vascular tone and microvascular function (Gómez et al., 2022) Metformin has been reported to have an anti-inflammatory effect. In a prospective study to investigate the anti-inflammatory effect of AMPK activation in vivo, metformin and AICAR was administered respectively to mice prior to LPS injection. LPS injection significantly increased the level of VCAM1 in the arterioles, peritubular capillaries, post capillary venules, and glomerulus in the kidneys as well as in the arterioles, alveolar capillaries, and venules in the lungs. Metformin and AICAR administration effectively reduced VCAM1 expression in the microvascular beds both in the kidneys and lungs. Furthermore, LPS-induced increase of the serum levels of pro-inflammatory cytokines TNF⍺ and IL-6 were both significantly decreased by metformin and AICAR (Tian et al., 2019). In a trial of patients receiving glucocorticoid treatment for various chronic inflammatory diseases, 12 weeks of treatment with metformin 2550 mg/day resulted in lower serum levels of high-sensitive CRP as compared to placebo. Furthermore, carbohydrate-challenged TNF-α levels increased significantly in the placebo-treated group but not in the metformin-treated group (Pernicova et al., 2020) In addition, metformin showed some antibacterial activity. A retrospective study conducted in 2022 has shown that at the cellular level, metformin modulates cell metabolism through transient inhibition of complex I of mitochondrial electron transport chain and activates AMPK that protects energy balance in the cell (Gómez et al., 2022). It enhances neutrophil chemotaxis and phagocytosis and bacterial clearance (Bai and Chen, 2021).

Some studies have shown that metformin has a beneficial effect in sepsis patients. In two retrospective studies of septic shock patients receiving metformin, it showed an improvement in inflammatory response and oxidative stress induced by sepsis which resulted in improved mortality at different doses of metformin (Gras et al., 2006; Doenyas-Barak et al., 2015) . In a systematic review and meta-analysis done by Liang et al for published observational cohort data to determine the association between preadmission metformin use and mortality in septic adult patients with diabetes mellitus, it was concluded that preadmission metformin users had lower mortality than non-users and this analysis suggested that the effect of metformin is related to its anti-inflammatory effect (Liang et al., 2019).

Metformin has not significant adverse effects; however, it may cause gastrointestinal upset that can be overcome by titration of the dose and administration with meals (Nasri and Rafieian-Kopaei, 2014) and a rare but serious condition called lactic acidosis with the following symptoms: dizziness, severe drowsiness, muscle pain, tiredness, chills, blue/cold skin, fast/difficult breathing, slow/irregular heartbeat, stomach pain with diarrhea, nausea or vomiting. Lactic acidosis usually occurs due to drug overdose or in some contraindicated conditions (Scheen and Paquot, 2013). Rare incidence of lactic acidosis has been reported with the use of metformin especially in patients with renal impairment, hence, metformin is contraindicated in those with creatinine clearance less than 45ml/min. In sepsis, previous study reported that patients hospitalized for suspected sepsis who were on metformin had slightly higher prevalence of hyperlactatemia than non- metformin users though non-metformin users were found to have a higher 28-days mortality risk than metformin users (Green et al., 2012). In another study, conducted to compare the prognosis of extremely elevated plasma lactate levels and septic shock between metformin users and non-users it was found that the rate of in hospital mortality was lower for those who were actively treated with metformin than those who were not. the prognosis of metformin users were better despite higher lactate levels (Doenyas-Barak et al., 2015). One last study was done to evaluate the impact of metformin use on lactate kinetics in septic patients and showed that lactate levels in metformin users were initially elevated in the early phase in severe sepsis and septic shock. However, there was no significant difference in lactate levels, lactate clearance and normalization over the initial 24 hours period based on metformin use (Park et al., 2017)

To the best of our knowledge our study will be the first prospective controlled randomized trial to assess the clinical outcome of metformin in patients with sepsis.

Conditions

Sepsis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Metformin arm

In this arm patients will administrate metformin 500 mg three times a day together with the standard care of sepsis.

Group Type: EXPERIMENTAL

Metformin

Intervention Type: DRUG

Patients in the intervention arm will take metformin 500mg three times a day

Control Arm

In this arm patients will receive the standard care of sepsis only

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Metformin

Patients in the intervention arm will take metformin 500mg three times a day

Intervention Type: DRUG

Other Intervention Names

Glucophage

Eligibility Criteria

Inclusion Criteria

• Age more than 18 years old.
• A diagnosis of sepsis according to the latest Sepsis-3 definition
• Estimated GFR >45 ml/min

Exclusion Criteria

• • Immunosuppressed or end stage cancer.

• Septic Shock.
• Pregnancy and breast feeding.
• Patients on metformin, Sodium glucose cotransporters or Gliptins.
• End stage hepatic disease.
• Contraindications to metformin (chronic respiratory failure, chronic cardiac failure, chronic kidney or liver disease, myocardial infarction within the last month).
• Patients with hypersensitivity to metformin.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

German University in Cairo

OTHER

Sponsor Role: lead

Responsible Party

Mai Tarek Ghannoum

Assistant Lecturer of Clinical Pharmacy

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Al Demerdash University Hospital

Cairo, , Egypt

Site Status: RECRUITING

Countries

Egypt

Central Contacts

Mai M.T Ghannoum, Assistant Lecturer

Role: CONTACT

mai.tarek@guc.edu.eg

002-01221054807

Mohamed H. Solayman, Lecturer

Role: CONTACT

mohamed.solayman@guc.edu.eg

002-01005882550

Facility Contacts

Mai M.T Ghannoum, Ass. Lecturer

Role: primary

mai.tarek@guc.edu.eg

01221054807 ext. 002

Mai Shawki, Ass. Prof

Role: backup

mannus.ahmed@yahoo.com

01001701461 ext. 002

Other Identifiers

FMASU MD146/2023

Identifier Type: -

Identifier Source: org_study_id